Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Total Debt (2016 - 2025)

Historic Total Debt for Heron Therapeutics (HRTX) over the last 5 years, with Q3 2025 value amounting to $107.5 million.

  • Heron Therapeutics' Total Debt rose 33292.65% to $107.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $107.5 million, marking a year-over-year increase of 33292.65%. This contributed to the annual value of $25.0 million for FY2024, which is 314.47% up from last year.
  • Latest data reveals that Heron Therapeutics reported Total Debt of $107.5 million as of Q3 2025, which was up 33292.65% from $25.2 million recorded in Q1 2025.
  • Over the past 5 years, Heron Therapeutics' Total Debt peaked at $107.5 million during Q3 2025, and registered a low of $24.0 million during Q3 2023.
  • Over the past 3 years, Heron Therapeutics' median Total Debt value was $24.7 million (recorded in 2024), while the average stood at $35.0 million.
  • Within the past 5 years, the most significant YoY rise in Heron Therapeutics' Total Debt was 33292.65% (2025), while the steepest drop was 313.33% (2025).
  • Quarter analysis of 3 years shows Heron Therapeutics' Total Debt stood at $24.3 million in 2023, then increased by 3.14% to $25.0 million in 2024, then surged by 329.5% to $107.5 million in 2025.
  • Its Total Debt stands at $107.5 million for Q3 2025, versus $25.2 million for Q1 2025 and $25.0 million for Q4 2024.